{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:51:41Z","timestamp":1791085901705,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,3,19]],"date-time":"2010-03-19T00:00:00Z","timestamp":1268956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The Malawi antiretroviral therapy (ART) programme uses the public health approach to identify ART failure. Advanced disease progression may occur before switching to second\u2010line ART. We report outcomes for patients evaluated and initiated on second\u2010line treatment in Malawi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients meeting Malawi immunological or clinical criteria for ART failure in two large urban ART clinics were evaluated for virological failure (viral load &gt;400 HIV\u20101 RNA copies\/mL) and, if failure was confirmed, initiated on second\u2010line ART (zidovudine\/lamivudine\/tenofovir\/lopinavir\/ritonavir). Patients were seen monthly and laboratory evaluations were performed quarterly and as needed. We performed logistic regression modelling to identify factors associated with mortality, mortality or new HIV illnesses, and virological suppression at 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 109 patients with confirmed virological failure, five patients died prior to initiation, three declined switching and 101 patients initiated second\u2010line treatment. Over 12 months, 10 additional patients died, 34 patients experienced 45 HIV\u2010related events, and 19 patients experienced grade 3 or 4 toxicities. Among survivors, 85.2% had HIV\u20101 RNA&lt;400\u2003copies\/mL at 12 months. While power to distinguish differences was limited, response rates were similar regardless of baseline resistance level. The median CD4 count increase was 142\u2003cells\/\u03bcL. World Health Organization clinical failure at baseline [odds ratio (OR) 3.47; 95% confidence interval (CI) 1.14\u201310.59] and body mass index &lt;18.5 (OR 4.43; 95% CI 1.15\u201317.12) were risk factors for death. Baseline CD4 count &lt;50\u2003cells\/\u03bcL was associated with increased risk for death or morbidity at 12 months (OR 2.57; 95% CI 1.01\u20136.52).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Second\u2010line treatment in Malawi was associated with substantial mortality, morbidity and toxicity but, among survivors, virological outcomes were favourable.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2010.00825.x","type":"journal-article","created":{"date-parts":[[2010,3,21]],"date-time":"2010-03-21T00:09:28Z","timestamp":1269130168000},"page":"510-518","source":"Crossref","is-referenced-by-count":78,"title":["Second\u2010line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline<sup>*<\/sup>"],"prefix":"10.1111","volume":"11","author":[{"given":"MC","family":"Hosseinipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Kumwenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LB","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Mzinganjira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Mhango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Eron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Phiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Van Oosterhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,4]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource\u2010Limited Settings: Toward Universal Access. Recommendations for a Public Health Approach","author":"World Health Organization.","year":"2006"},{"key":"e_1_2_6_3_2","volume-title":"Treatment of AIDS: Guidelines for the Use of Antiretroviral Therapy in Malawi","author":"Ministry of Health Malawi.","year":"2006"},{"key":"e_1_2_6_4_2","volume-title":"Quarterly Report of the Antiretroviral Treatment Programme in Malawi with Results up to 31st December 2008","author":"Department of HIV and AIDS Ministry of Health.","year":"2008"},{"key":"e_1_2_6_5_2","volume-title":"Treatment of AIDS. Guidelines for the Use of Antiretroviral Therapy in Malawi","author":"Ministry of Health Malawi.","year":"2008"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200412150-00009"},{"key":"e_1_2_6_7_2","first-page":"795","article-title":"Lamivudine monotherapy in HIV\u20101\u2010infected patients harbouring a lamivudine\u2010resistant virus","volume":"20","author":"Castagna A","year":"2006","journal-title":"a randomized pilot study (E-184V study)"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7542804"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/430709"},{"issue":"9","key":"e_1_2_6_10_2","first-page":"1127","article-title":"The public health approach to identify antiretroviral therapy failure","volume":"23","author":"Hosseinipour MC","year":"2009","journal-title":"high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/510745"},{"key":"e_1_2_6_12_2","first-page":"280","article-title":"Lopinavir\/ritonavir as single\u2010drug therapy for maintenance of HIV\u20101 viral suppression","volume":"40","author":"Arribas JR","year":"2005","journal-title":"48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn103"},{"key":"e_1_2_6_14_2","unstructured":"Division of AIDS National Institutes of Health.Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2004. Available atwww3.niaid.nih.gov\/LabsAndResources\/resources\/DAIDSClinRsrch\/PDF\/DAIDSAEGradingTable.pdf(accessed 16 June 2009)."},{"key":"e_1_2_6_15_2","first-page":"138","article-title":"Update of the drug resistance mutations in HIV\u20101","volume":"16","author":"Johnson VA","year":"2008","journal-title":"Top HIV Med"},{"key":"e_1_2_6_16_2","first-page":"817","article-title":"Mortality of HIV\u20101\u2010infected patients in the first year of antiretroviral therapy","volume":"367","author":"Braitstein P","year":"2006","journal-title":"comparison between low-income and high-income countries"},{"key":"e_1_2_6_17_2","first-page":"782","article-title":"Rapid scale\u2010up of antiretroviral therapy at primary care sites in Zambia","volume":"296","author":"Stringer JS","year":"2006","journal-title":"feasibility and early outcomes"},{"key":"e_1_2_6_18_2","first-page":"1335","article-title":"Scaling up of highly active antiretroviral therapy in a rural district of Malawi","volume":"367","author":"Ferradini L","year":"2006","journal-title":"an effectiveness assessment"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051908"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830007cd"},{"key":"e_1_2_6_21_2","first-page":"1305","article-title":"Second\u2010line antiretroviral therapy in resource\u2010limited settings","volume":"22","author":"Pujades\u2010Rodriguez M","year":"2008","journal-title":"the experience of M\u00e9decins Sans Fronti\u00e8res"},{"key":"e_1_2_6_22_2","first-page":"103","article-title":"Lessons learned from a paying antiretroviral therapy service in the public health sector at Kamuzu Central Hospital, Malawi","volume":"5","author":"Hosseinipour MC","year":"2006","journal-title":"1-year experience"},{"key":"e_1_2_6_23_2","first-page":"2141","article-title":"Early mortality among adults accessing a community\u2010based antiretroviral service in South Africa","volume":"19","author":"Lawn SD","year":"2005","journal-title":"implications for programme design"},{"key":"e_1_2_6_24_2","first-page":"86","article-title":"Effectiveness of antiretroviral treatment in a South African program","volume":"168","author":"Fairall LR","year":"2008","journal-title":"a cohort study"},{"key":"e_1_2_6_25_2","first-page":"49","article-title":"Efficacy and safety of darunavir\u2010ritonavir compared with that of lopinavir\u2010ritonavir at 48 weeks in treatment\u2010experienced, HIV\u2010infected patients in TITAN","volume":"370","author":"Madruga JV","year":"2007","journal-title":"a randomised controlled phase III trial"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/496892"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"key":"e_1_2_6_28_2","first-page":"191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral\u2010naive patients","volume":"292","author":"Gallant JE","year":"2004","journal-title":"a 3-year randomized trial"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000243103.03265.2b"},{"key":"e_1_2_6_30_2","volume-title":"Renal Function after Use of Tenofovir as Part of the Initial ART Regimen","author":"Moore R","year":"2008"},{"key":"e_1_2_6_31_2","volume-title":"Comparison of Renal Function on NNRTI vs. Boosted PI Based Tenofovir Based Regimens","author":"Short WR","year":"2008"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00442.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl552"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1553-1560.2004"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282faa71e"},{"key":"e_1_2_6_36_2","unstructured":"World Health Organization.17th Expert Committee on the Selection and Use of Essential Medicines. 2009. Available athttp:\/\/www.who.int\/selection_medicines\/committees\/expert\/17\/en\/index.html (accessed6 July 2009)."},{"issue":"8","key":"e_1_2_6_37_2","first-page":"856","article-title":"Diagnosis of antiretroviral therapy failure in Malawi","volume":"14","author":"Van Oosterhout JJ","year":"2009","journal-title":"poor performance of clinical and immunological WHO criteria"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e4cd8"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283262a78"},{"key":"e_1_2_6_40_2","first-page":"1443","article-title":"Outcomes from monitoring of patients on antiretroviral therapy in resource\u2010limited settings with viral load, CD4 cell count, or clinical observation alone","volume":"371","author":"Phillips AN","year":"2008","journal-title":"a computer simulation model"},{"key":"e_1_2_6_41_2","unstructured":"CoutinhoA MerminJ EkwaruJPet al. Utility of routine viral load CD4 cell count and clinical monitoring among HIV\u2010infected adults in Uganda: a randomized trial.15th Conference on Retroviruses and Opportunistic Infections. Boston MA 2008 [Abstract 125]."},{"key":"e_1_2_6_42_2","unstructured":"MugyenyiP WalkerS HakimJet al. eds. Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART) initiation on clinical disease progression of HIV\u2010infected African adults: the DART Trial final results.5th Conference on HIV Pathogenesis Treatment and Prevention. International AIDS Society Cape Town South Africa 2009 [Abstract TUSS102]."},{"key":"e_1_2_6_43_2","unstructured":"LaraAM KigoziJ AmurwonJet al. eds. Cost Effectiveness analysis of routine laboratory or clinically driven strategies for monitoring antiretroviral therapy in Uganda and Zimbabwe (DART trial).5th Conference on HIV Pathogenesis Treatment and Prevention. International AIDS society Cape Town South Africa 2009 [Abstract TUSS103]."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2010.00825.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2010.00825.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:37:25Z","timestamp":1698640645000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2010.00825.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,4]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1468-1293.2010.00825.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00825.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,4]]}}}